Structure-activity relationships of antimicrobial and lipoteichoic acid-sequestering properties in polyamine sulfonamides

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 1, 2009, Pages 57-62

  Warshakoon, Hemamali J ^a   Burns, Mark R ^b   David, Sunil A ^a,c  

^a UNIVERSITY OF KANSAS   (United States)

^b MediQuest Therapeutics Inc   (United States)

^c Multidisciplinary Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; POLYAMINE DERIVATIVE; SPERMINE; SULFONAMIDE; TOLL LIKE RECEPTOR 2;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CELL ACTIVATION; CONTROLLED STUDY; DRUG BINDING; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

ANTI-INFECTIVE AGENTS; CELL LINE; ESCHERICHIA COLI; HUMANS; LIPOPOLYSACCHARIDES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NF-KAPPA B; POLYAMINES; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TEICHOIC ACIDS; TOLL-LIKE RECEPTOR 2;

EID: 59749088258     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00812-08     Document Type: Article

References (49)

1. Baddiley, J. 1989. Bacterial cell walls and membranes. Discovery of the teichoic acids. Bioessays 10:207-210.
2. Balakrishna, R., S. J. Wood, T. B. Nguyen, K. A. Miller, E. V. Suresh Kumar, A. Datta, and S. A. David. 2006. Structural correlates of antibacterial and membrane-permeabilizing activities in acylpolyamines. Antimicrob. Agents Chemother. 50:852-861.
3. Bhattacharjya, S., S. A. David, V. I. Mathan, and P. Balaram. 1997. Polymyxin B nonapeptide: conformations in water and in the lipopolysaccharide-bound state determined by two-dimensional NMR and molecular dynamics. Biopolymers 41:251-265.
4. Bone, R. C. 1994. Gram-positive organisms and sepsis. Arch. Intern. Med. 154:26-34.
5. Burns, M. R., S. A. Jenkins, M. R. Kimbrell, R. Balakrishna, T. B. Nguyen, B. G. Abbo, and S. A. David. 2007. Polycationic sulfonamides for the sequestration of endotoxin. J. Med. Chem. 50:877-888.
6. Burns, M. R., S. A. Jenkins, N. M. Vermeulen, R. Balakrishna, T. B. Nguyen, M. R. Kimbrell, and S. A. David. 2006. Structural correlation between lipophilicity and lipopolysaccharide-sequestering activity in spermine-sulfonamide analogs. Bioorg. Med. Chem. Lett. 16:6209-6212.
7. Burns, M. R., S. J. Wood, K. A. Miller, T. Nguyen, J. R. Cromer, and S. A. David. 2005. Lysine-spermine conjugates: hydrophobic polyamine amides as potent lipopolysaccharide sequestrants. Bioorg. Med. Chem. 13:2523-2536.
8. Centers for Diseases Control and Prevention. 1990. Increases in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR Morb. Mortal. Wkly. Rep. 39:31-34.
9. Coley, J., M. Duckworth, and J. Baddiley. 1972. The occurrence of lipoteichoic acids in the membranes of gram-positive bacteria. J. Gen. Microbiol. 73:587-591.
10. David, S. A. 2001. Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules. J. Mol. Recognit. 14:370-387.
11. David, S. A., K. A. Balasubramanian, V. I. Mathan, and P. Balaram. 1992. Analysis of the binding of polymyxin B to endotoxic lipid A and core glycolipid using a fluorescent displacement probe. Biochim. Biophys. Acta 1165:147-152.
12. David, S. A., V. I. Mathan, and P. Balaram. 1995. Interactions of linear dicationic molecules with lipid A: structural requisites for optimal binding affinity. J. Endotoxin Res. 2:325-336.
13. Deininger, S., I. Figueroa-Perez, S. Sigel, A. Stadelmaier, R. R. Schmidt, T. Hartung, and S. von Aulock. 2007. Use of synthetic derivatives to determine the minimal active structure of cytokine-inducing lipoteichoic acid. Clin. Vaccine Immunol. 14:1629-1633.
14. Deininger, S., A. Stadelmaier, S. von Aulock, S. Morath, R. R. Schmidt, and T. Hartung. 2003. Definition of structural prerequisites for lipoteichoic acid-inducible cytokine induction by synthetic derivatives. J. Immunol. 170:4134-4138.
15. Falagas, M. E., and S. K. Kasiakou. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341.
16. Figueroa-Perez, I., A. Stadelmaier, S. Deininger, S. Aulock, T. Hartung, and R. R. Schmidt. 2006. Synthesis of Staphylococcus aureus lipoteichoic acid derivatives for determining the minimal structural requirements for cytokine induction. Carbohydr. Res. 341:2901-2911.
17. Fischer, W. 1994. Lipoteichoic acid and lipids in the membrane of Staphylococcus aureus. Med. Microbiol. Immunol. 183:61-76.
18. Galanos, C., O. Lüderitz, E. T. Rietschel, O. Westphal, H. Brade, L. Brade, M. A. Freudenberg, U. F. Schade, M. Imoto, S. Yoshimura, S. Kusumoto, and T. Shiba. 1985. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur. J. Biochem. 148:1-5.
19. Gao, J. J., Q. Xue, E. G. Zuvanich, K. R. Haghi, and D. C. Morrison. 2001. Commercial preparations of lipoteichoic acid contain endotoxin that contributes to activation of mouse macrophages in vitro. Infect. Immun. 69:751-757.
20. Gasche, Y., D. Pittet, and P. Sutter. 1995. Outcome and prognostic factors in bacteremic sepsis, p. 35-51. In W. J. Sibbald and J. L. Vincent (ed.), Clinical trials for treatment of sepsis. Springer-Verlag, Berlin, Germany.
21. Hancock, R. E. 2001. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1:156-164.
22. Hashimoto, M., M. Furuyashiki, R. Kaseya, Y. Fukada, M. Akimaru, K. Aoyama, T. Okuno, T. Tamura, T. Kirikae, F. Kirikae, N. Eiraku, H. Morioka, Y. Fujimoto, K. Fukase, K. Takashige, Y. Moriya, S. Kusumoto, and Y. Suda. 2007. Evidence of immunostimulating lipoprotein existing in the natural lipoteichoic acid fraction. Infect. Immun. 75:1926-1932.
23. Hashimoto, M., K. Tawaratsumida, H. Kariya, K. Aoyama, T. Tamura, and Y. Suda. 2006. Lipoprotein is a predominant Toll-like receptor 2 ligand in Staphylococcus aureus cell wall components. Int. Immunol. 18:355-362.
24. Hashimoto, M., K. Tawaratsumida, H. Kariya, A. Kiyohara, Y. Suda, F. Krikae, T. Kirikae, and F. Gotz. 2006. Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J. Immunol. 177:3162-3169.
25. Hashimoto, M., J. Yasuoka, Y. Suda, H. Takada, T. Yoshida, S. Kotani, and S. Kusumoto. 1997. Structural feature of the major but not cytokine-inducing molecular species of lipoteichoic acid. J. Biochem. (Tokyo) 121:779-786.
26. Hodgin, K. E., and M. Moss. 2008. The epidemiology of sepsis. Curr. Pharm. Des. 14:1833-1839.
27. Imoto, M., H. Yoshimura, S. Kusumoto, and T. Shiba. 1984. Total synthesis of lipid A, active principle of bacterial endotoxin. Proc. Japan. Acad. Sci. 60:285-288.
28. Kimbrell, M. R., H. Warshakoon, J. R. Cromer, S. Malladi, J. D. Hood, R. Balakrishna, T. A. Scholdberg, and S. A. David. 2008. Comparison of the immunostimulatory and proinflammatory activities of candidate gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells. Immunol. Lett. 118:132-141.
29. Kohlenberg, A., F. Schwab, C. Geffers, M. Behnke, H. Ruden, and P. Gastmeier. 2008. Time-trends for gram-negative and multidrug-resistant gram-positive bacteria associated with nosocomial infections in German intensive care units between 2000 and 2005. Clin. Microbiol. Infect. 14:93-96.
30. Kragsbjerg, P., H. Holmberg, and T. Vikerfors. 1996. Dynamics of blood cytokine concentrations in patients with bacteremic infections. Scand. J. Infect. Dis. 28:391-398.
31. Laursen, J. B., J. Nielsen, T. Haack, S. Pusuluri, S. David, R. Balakrishna, Y. Zeng, Z. Ma, T. B. Doyle, and L. A. Mitscher. 2006. Further exploration of antimicrobial ketodihydronicotinic acid derivatives by multiple parallel syntheses. Comb. Chem. High Throughput Screen. 9:663-681.
32. Levy, M. M., M. P. Fink, J. C. Marshall, E. Abraham, D. Angus, D. Cook, J. Cohen, S. M. Opal, J. L. Vincent, and G. Ramsay. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 29:530-538.
33. Li, J., R. L. Nation, J. D. Turnidge, R. W. Milne, K. Coulthard, C. R. Rayner, and D. L. Paterson. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
34. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348:1546-1554.
35. Miller, K. A., E. V. K. Suresh Kumar, S. J. Wood, J. R. Cromer, A. Datta, and S. A. David. 2005. Lipopolysaccharide sequestrants: structural correlates of activity and toxicity in novel acylhomospermines. J. Med. Chem. 48:2589-2599.
36. Morath, S., A. Geyer, and T. Hartung. 2001. Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J. Exp. Med. 193:393-397.
37. Morath, S., A. Stadelmaier, A. Geyer, R. R. Schmidt, and T. Hartung. 2002. Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J. Exp. Med. 195:1635-1640.
38. Moss, M., and G. S. Martin. 2004. A global perspective on the epidemiology of sepsis. Intensive Care Med. 30:527-529.
39. Nguyen, T. B., A. Adisechan, E. V. K. Suresh Kumar, R. Balakrishna, M. R. Kimbrell, K. A. Miller, A. Datta, and S. A. David. 2007. Protection from endotoxic shock by EVK-203, a novel alkylpolyamine sequestrant of lipopolysaccharide. Bioorg. Med. Chem. 15:5694-5709.
40. Rodriguez-Creixems, M., L. Alcala, P. Munoz, E. Cercenado, T. Vicente, and E. Bouza. 2008. Bloodstream infections: evolution and trends in the microbiology workload, incidence, and etiology, 1985-2006. Medicine (Baltimore) 87:234-249.
41. Rosenthal, K. S., and D. R. Storm. 1977. Disruption of the Escherichia coli outer membrane permeability barrier by immobilized polymyxin B. J. Antibiot. 30:1087-1092.
42. Safdar, A., G. H. Rodriguez, M. Balakrishnan, J. J. Tarrand, and K. V. Rolston. 2006. Changing trends in etiology of bacteremia in patients with cancer. Eur. J. Clin. Microbiol. Infect. Dis. 25:522-526.
43. Sarkar, S., E. R. DeSantis, and J. Kuper. 2007. Resurgence of colistin use. Am. J. Health Syst. Pharm. 64:2462-2466.
44. Scott, M. G., M. R. Gold, and R. E. Hancock. 1999. Interaction of cationic peptides with lipoteichoic acid and gram-positive bacteria. Infect. Immun. 67:6445-6453.
45. Sil, D., A. Shrestha, M. R. Kimbrell, T. B. Nguyen, A. K. Adisechan, R. Balakrishna, B. G. Abbo, S. Malladi, K. A. Miller, S. Short, J. R. Cromer, S. Arora, A. Datta, and S. A. David. 2007. Bound to shock: protection from lethal endotoxemic shock by a novel, nontoxic, alkylpolyamine lipopolysaccharide sequestrant. Antimicrob. Agents Chemother. 51:2811-2819.
46. Stadelmaier, A., S. Morath, T. Hartung, and R. R. Schmidt. 2003. Synthesis of the first fully active lipoteichoic acid. Angew. Chem. Int. Ed. Engl. 42:916-920.
47. Storm, D. R., and K. Rosenthal. 1977. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem. 46:723-763.
48. Vergidis, P. I., and M. E. Falagas. 2008. Multidrug-resistant gram-negative bacterial infections: the emerging threat and potential novel treatment options. Curr. Opin. Investig. Drugs 9:176-183.
49. Yuan, Z., and V. H. Tam. 2008. Polymyxin B: a new strategy for multidrug-resistant gram-negative organisms. Expert. Opin. Investig. Drugs 17:661-668.